India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.
The advanced machine learning model tracks more than 50 different factors to make its predictions. It has already been found to be more accurate than popular prediction methods for heart disease that are currently available.
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Christopher M. Kramer, MD, is a longtime cardiologist and cardiac imaging specialist. His one-year term as the head of the American College of Cardiology officially began at the end of ACC.25 in Chicago.
This week, Heart Rhythm Advocates announced its establishment and called on cardiologists and EPs to support its efforts with membership and joining committees to guide efforts.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting in late March, showed positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).
Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
